Although early clinical studies have shown promising specificity, comparative data with other molecular imaging targets, such as CAIX or PSMA, remain limited, warranting trials with larger sample sizes for validating CD70‐targeted immuno‐PET/CT's diagnostic utility across RCC subtypes and other malignancies characterized by CD70 overexpression. This evidence concerns the gene CD70 and renal cell carcinoma.